CN108276491A - monoclonal antibody capable of specifically recognizing HPV 18L 1 protein and application thereof - Google Patents
monoclonal antibody capable of specifically recognizing HPV 18L 1 protein and application thereof Download PDFInfo
- Publication number
- CN108276491A CN108276491A CN201810110881.0A CN201810110881A CN108276491A CN 108276491 A CN108276491 A CN 108276491A CN 201810110881 A CN201810110881 A CN 201810110881A CN 108276491 A CN108276491 A CN 108276491A
- Authority
- CN
- China
- Prior art keywords
- ser
- gly
- leu
- thr
- val
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
Abstract
the invention relates to a monoclonal antibody capable of specifically recognizing HPV 18L 1 protein, which comprises a heavy chain region and a light chain region, wherein the sequence of the heavy chain region is SEQ ID NO:1 or 3 or a sequence with 80% consistency with SEQ ID NO:1 or 3, the sequence of the light chain region is SEQ ID NO:2 or 4 or a sequence with 80% consistency with SEQ ID NO:1 or 3, the invention also relates to application of the monoclonal antibody in preparing an HPV18 detection reagent, and also relates to an HPV18 detection kit containing the monoclonal antibody.
Description
Technical field
The present invention relates to HPV infection detection field, more specifically it relates to which a kind of can specific recognition HPV18L1 albumen
Monoclonal antibody and its application, and its prepare diagnostic kit.
Background technology
Human papilloma virus (Human Papillomavirus, abbreviation HPV) be it is a kind of it is wide-spread, cause condyloma
The pathogen that spreads through sex intercourse.HPV is a kind of papilloma vacuolating virus A categories belonging to papovaviridae, and spherical DNA virus is one
The thermophilic epithelial virus of kind, has the specificity of height, the scaly epithelium of human skin mucous membrane can be caused to be proliferated.HPV hypotypes are extremely more, mesh
It is preceding it is separated go out more than 130 to plant, different types causes different clinical manifestations.According to clinical consequences caused by infection, HPV points are
High-risk-type (HPV16,18,31,33,35,39,45,51,52,56,58,59,68,73,82 etc.) and low risk (such as HPV6,11,
40,42-44,54,61,70,72,81 etc.).Most HPV infection can fully recover in 1-2, these low risks HPV mainly causes to give birth to
Grow the exophytic condyloma class lesion, condyloma class lesion and low cervical intraepithelial neoplasia sample of anal skin and vagina lower part
Become (CINI), be in it is transient, can Natural Reversal.High-risk HPV mainly results in Carvical intraepithelial neoclassic (CINII-III grades)
With the generation of cervical carcinoma, I grade of CIN for continuing high-risk HPV infection easily progresses to CIN II~III, leads to the hair of women cervical carcinoma
It is raw.Cervical carcinoma is the second largest lethal carninomatosis of women, and clinic proves cases of cervical cancer and the high-risk HPV virus sense of 95-99.7%
It is infected with pass, i.e. HPV infection is the prerequisite necessary initiation conditions of uterine neck carcinogenesis.Scientific research finds at least 20 kinds of high-risk-types
Early stage infiltrations and invasive endometrial neck cancer of the HPV with 95% are related, and bis- hypotypes of especially HPV16 and HPV18 are cervical carcinomas
Main inducing, two hypotypes of 70% or more cervical carcinoma and this are related.
Cervical carcinoma is to threaten one of the most common malignant tumour of global women's health, the infection of HPV in women population
Rate is 13.5% or so.The whole world is every year there are about cervical carcinoma new cases 52.8 ten thousand, with the relevant death toll of cervical carcinoma up to 26.6
Ten thousand, data in 2017 shows China every year there are about 130,000 cervical carcinoma new cases, and death is 30,000.Use polymerase
Chain reaction (PCR) carries out in HPV DNA typings 253 different cervical lesions, by chronic cervicitis, Pseudocondyloma, wart sample disease
Become, condyloma acuminatum, CIN and cervical carcinoma sequence, HPV positive rates be in trend incremented by successively, respectively 16.7%, 29.8%,
37.5%, 61.7%, 79.7% and 90.9%.Using situ PCR (ISPCR) to 44 cervical carcinomas, 18 cancer beside organisms
And 30 chronic cervicitis and HPV16DNA in 15 normal cervical tissues and HPV18DNA be detected after find 44 palaces
HPV16DNA is 79.5%, HPV18DNA of the positive positives 11.3% in neck cancer tissue；15 cancer beside organisms are with CINII-III
Grade, the HPV16DNA positives 80%, 15 normal cervical tissues HPV DNA are negative.These all illustrate precancerous lesions of uterine cervix, uterine neck
Cancer is infected with high-risk HPV, and especially HPV16/18 infection is closely related, and with the exacerbation of lesion degree, HPV16/18 inspections
Extracting rate increases, and illustrates that it is the important indicator for predicting cervical carcinoma to detect HPV16/18.But in the world in most cases only in uterine neck
There are when apparent lesion, just high-risk HPV is detected, often misses best intervention and therapic opportunity.Therefore early stage
Parting detection is carried out to HPV, it is very necessary to detect high-risk HPV hypotypes (especially HPV16/18).
Following benefit can be brought to the parting detection of HPV16/18：1) early stage offer diagnosis early warning can be infected in virus；2)
The sense of the other high-risk hypotype of single type can be shown as the evaluation index of medical treatment effect, twice in succession HPV partings detection
The possibility of dye, display uterine neck carcinogenesis increases, and should cause greatly to pay attention to；3) infection of HPV accounts for mainly in different areas
The type of position is different, and parting detection favorably carries out the prevention and control of HPV infection for various regions research, using vaccine.
Common HPV detection methods have ThinPrep cytologic test (TCT) and HPV nucleic acid detection.TCT mainly passes through sight
It examines cell morphology characteristic to be diagnosed, this method is noninvasive, easy, therefore, clinically can be as in cervical carcinoma screening
Primary dcreening operation has certain directive function to subsequent inspection and treatment.But TCT detection artificial subjective factors are big, can not definitely know
The hypotype that the stage of road HPV infection and HPV specifically infect.
HPV nucleic acid detects the HPV hypotypes that can determine infection, generally by real-time fluorescence PCR method or hybrid capture come real
It is existing.The required equipment of both methods is all more expensive, and cumbersome to the diagnostic operation of different genotype HPV, is not suitable for
In the extensive screening to cervix cancer.Commercialized hybrid capture kit can detect that clinical sample without PCR amplification
HPV DNA in product, and two class of high-risk-type and low risk can be distinguished, but such kit is fubaritic to go out to infect HPV's
Specific genotype.In addition testing result can only show that HPV viruse gene exists, and cannot detect state existing for HPV viruse, be living
Jump replicates or dead virus, it cannot be determined whether being in recovery and prognosis.
Therefore, it is necessary to a kind of new HPV infection detection kits.
Invention content
HPV L1 albumen is the viral capsid proteins of HPV, and different HPV hypotypes encode different capsid proteins, is existed
It can reflect that HPV viruse is in and enliven duplicate stage.Result of study show high-risk HPV L1 glutelins positive expression rate with
Downward trend is presented in its expression of the exacerbation of cervical lesions degree.Clinically detect that the high-risk HPV L1 glutelin positives illustrate machine
Body is in duplicate stage by the infection and virus of high-risk HPV.Therefore, can by specifically detect HPV L1 glutelins come
Detect HPV infection hypotype and Infection Status.Inventor in the course of the research, has selected the distinctive amino acid sequence synthesis of HPV18
Antigen, and with this induce to have obtained the highly specific monoclonal antibody for HPV18 L1 albumen.
Based on the above research, invention provide it is a kind of can specific recognition HPV18 L1 albumen monoclonal antibody, it is special
Sign is, including heavy chain region and light chain area, wherein the sequence of the heavy chain region is SEQ ID NO:1 or 3, or with SEQ ID
NO:1 or 3 sequences with 80% consistency；The sequence in the light chain area is SEQ ID NO:2 or 4, or with SEQ ID NO:
1 or 3 sequences with 80% consistency.
In a preferred embodiment, SEQ ID NO:CDR region there are three tools in 1, respectively 26-33 sections,
52-58 sections and 97-106 sections.
In a preferred embodiment, SEQ ID NO:Tool is there are three CDR region in 2, respectively the (27-37 sections,
55-57 sections and 95-103 sections.
In one embodiment, the sequence of the heavy chain region is selected from SEQ ID NO:1、3、5-7.
In one embodiment, the sequence in the light chain area is selected from SEQ ID NO:2、4、8-20.
In a preferred embodiment, the heavy chain domain sequence of the monoclonal antibody is SEQ ID NO:1, sequence of light chain
For SEQ ID NO:19.
In a preferred embodiment, the heavy chain domain sequence of the monoclonal antibody is SEQ ID NO:6, sequence of light chain
For SEQ ID NO:2.
The invention also discloses application of the said monoclonal antibody in preparing HPV18 detection reagents.
The invention also discloses a kind of kits for detecting HPV18 infection comprising said monoclonal antibody.
Preferably, the kit is ELISA kit, including captures antibody and detection antibody, and the capture antibody is
Monoclonal antibody described in any one of claim 1-7, the detection antibody are using HPV18 L1 glutelins as antigen
The polyclonal antibody of preparation.
The invention also discloses a kind of methods of detection HPV18, including use said monoclonal antibody or its examination prepared
The step of agent or kit detect the pathological sample from patient.
By using monoclonal antibody of the invention and its it is the reagent prepared and kit, can detect that and live in HPV
The patient of dynamic infection period, easy to detect, specificity is high.
Description of the drawings
Fig. 1 is the statistics that ELISA detects different immunized mice serum for the serum titer of the naked peptide L1M186 of immunogene
Figure；
Fig. 2 is the statistical chart that ELISA detects 4 plants of monoclonal cell supernatants and the affinity of L1M186 polypeptides；
Fig. 3 be based on the QSPVP amino acid fixed point in L1M186 polypeptides sport one by one the not homopolypeptide of alanine (A) with
The amino acid of the statistical chart of the affinity of 10C9 or 10D8 antibody, underscore mark is that QSPVP corresponding position amino acid mutations are
Alanine；
Fig. 4 is the statistical chart for the antibody subtype that LISA detection kits measure 10C9 and 10D8；
Fig. 5 is the statistical chart of 16 mutant clons and HPV18 L1 glutelin affinity；
Fig. 6 is comparison of the wild type with 15 with the protein sequence of the higher mutant clon of HPV18 L1 glutelin affinity
Figure；
Fig. 7 monoclonal antibodies carry out the clinical sample of different HPV hypotypes in the photo of fluorescent staining；
Fig. 8 is the statistical chart that HPV18 ELISA detection kits detect different subtype HPV infection person；
Fig. 9 is the statistic curve that HPV18 ELISA detection kits detect HPV18 L1 albumen sensitivity；
Figure 10 is the statistic curve that HPV18 ELISA detection kits detect HPV18 L1 particle sensitivity.
Specific implementation mode
Principles and features of the present invention are described below in conjunction with example, the given examples are served only to explain the present invention, and
It is non-to be used to limit the scope of the present invention.
1. lmmunogen design is prepared with monoclonal antibody
We, which have synthesized, contains the modified polypeptide (L1M186) from HPV18 L1 protein-specific epitopes QSPVP；And
L1M186 coupling hemocyanin (KLH) is constituted into L1M186-KLH as immunogene.
Immunogene is dissolved in phosphate buffer (PBS, pH7.4) a concentration of 1mg/ml.It carried out just exempting from the 0th week, every
It is fully emulsified that mouse takes the immunogen solution of 100 μ l 1mg/ml to be carried out with 100 μ l Freund's complete adjuvants, forms the breast of Water-In-Oil
Turbid carries out multiple spot abdominal part hypodermic and is immunized, 6 mouse are immunized.Respectively in the 2nd week, 5 weeks, 8 weeks, 11 weeks booster immunizations 4
It is secondary, the emulsion of the polypeptide solution and 50 μ l incomplete Freund's adjuvants of each every 50 μ l 1mg/ml of mouse immune；6th week, 9
Week, 12 weeks take a blood sample.
The splenocyte of 1 week interior murine myeloma cell (Sp2/0) and immune mouse routinely PEG after last time is immune
Method merges, limiting dilution assay clone cell, and indirect ELISA screens specific antibody, and positive cell is continuously subcloned 2 times, gram
Cell strain after Longhua is after passage is determined as stable cell strain, Liquid nitrogen storage.The monoclonal cell strain of acquisition is injected to
Abdominal cavity prepares ascites.
The results are shown in Figure 1 by the ELISA of mice serum antibody, and 3 mean titres for exempting from rear 6 mouse are 10600 times of dilutions；
The 4 serum mean titres for exempting from rear 6 mouse are 46900 times of dilutions, and the 5 serum mean titres for exempting from rear 6 mouse are 72500 times dilute
It releases.The above experimental result shows that serum titer is in increasing trend with the increase of immune time, and illustrating that L1M186-KLH is immune is
Successfully, the specific antibody of high-affinity is induced.After 5 exempt from, since serum titer is most for 5# mouse (triangle mark)
Height reaches 102400 times of dilutions；Therefore cell fusion and subclone are carried out after selection is immune to the impact of 5# mouse, and obtains four
Strain monoclonal cell 1B3,10A8,10C9 and 10D8.
To monoclonal cell supernatant ELISA testing results as shown in Fig. 2, compared with the cell conditioned medium of 1B3 and 10A8,10C9
Show that better combination, readings are all higher than 2.0 with immunogene polypeptide L1M186 with the cell conditioned medium of 10D8；10C9 and 10D8 simultaneously
It is not reacted with HPV16 isoform polypeptide L1M161, and the other polypeptide L1M185 and L1M188 of HPV18.These result explanations
The L1M186 polypeptides of the cell conditioned medium energy specific recognition HPV18 of 10C9 and 10D8 do not intersect anti-with other unrelated polypeptides
It answers.
2. Identification of Monoclonal Antibodies
2.1 Epitope Identification
5 amino acid of QSPVP in L1M186 polypeptides are carried out to the not homopolypeptide packet of alanine (A) rite-directed mutagenesis one by one
Carried out ELISA detections.The results are shown in Figure 3, and antibody 10C9 and 10D8 is 1.6 with original L1M186 polypeptide associated values, when
First aspartic acid (Q) of L1M186 polypeptides, third position proline (P) or the 4th valine (V) sport alanine (A)
Afterwards, the associated value of ELISA falls to blank control level, illustrates these three amino acid of Q, P, V in 10C9 and 10D8 and L1M186
Polypeptide plays vital effect in combining, and is the important epitope that antibody combines.In addition when the second in L1M186 polypeptides
After serine (S) and the 5th proline (P) sport alanine (A), half has also dropped in ELISA associated values, thus illustrates this
Two amino acid also play critically important effect in the combination of 10C9 and 10D8 and L1M186 polypeptides, but are closed not as QPV
Key.The experimental results showed that, the antibody binding epitope of 10C9 and 10D8 are QSPVP, and wherein QPV plays vital work above
With.The detection display of ELISA parting detecting reagents, 10C9 and 10D8 are IgG1 hypotypes monoclonal antibody (Fig. 4).
2.2 monoclonal antibody affinity are identified
In order to detect the affinity of 10C9 and 10D8 and L1 albumen, we are detected using surface plasma resonance technology
10C9 and 10D8 is respectively 6.6x10 to the affinity of L1-HPV18 albumen-8And 3.5x10-9, as a result show 10C9 and 10D8 couples
HPV18 L1 albumen has very strong affinity.
2.3 monoclonal antibody sequences measure
After the monoclonal cell strain for obtaining 10C9 and 10D8, we are extracted RNA in the cell strain, are reversed to simultaneously
CDNA expands antibody scFv gene, and is sequenced, and after codon translation, obtains the VH sequence SEQ ID NO of 10C9:1
With VL sequence SEQ ID NO:2；And the VH sequence SEQ ID NO of 10D8:3 and VL sequence SEQ ID NO:4.Wherein, 10C9
VH sequences tool there are three CDR region, respectively 26-33 sections, 52-58 sections and 97-106 sections；10C9
VL sequences tool there are three CDR region, respectively 27-37 sections, 55-57 sections and 95-103 sections.
The CDR region of 10C9 is carried out to the saturation mutation of amino acid, and is built into corresponding 10C9 affinity maturations bacteriophage
Antibody library.ELISA testing results as shown in figure 5, in the phage library of the 10C9 mutant arrived by L1-HPV18 protein enrichments,
Pick wherein 48 bacteriophage monoclonals do further with the ELISA of L1-HPV18 albumen verify, experimental result such as Fig. 5 institutes
Show there is 16 clone (10C9-041 to 10C9-056) displays and L1-HPV18 protein bindings.The antibody sequence of wherein 10C9-044
Row are completely the same with the sequence of wild type 10C9, and the ELISA associated values of monoclonal phage are 0.35, illustrate L1-HPV18 eggs
The experiment of white enrichment phage library is successful.It is worth noting that there are two monoclonal phage 10C9053 and 10C9055 with
The associated value of L1-HPV18 albumen is respectively 1.25 and 0.73, compared with wild type 10C9-044 bacteriophage associated values, is had aobvious
The raising of work prompts the mutant form of both 10C9 that may can significantly improve the affinity of 10C9 and L1-HPV18 albumen.
This 16 clone alignments as shown in fig. 6, and this 16 clone in, 10C9-054,10C9-055 and
The VH sequences of 10C9-056 such as SEQ ID NO:Shown in 5-7, the VH sequences such as SEQ ID NO of remaining clone:Shown in 1.10C9-
041、10C9-042、10C9-043、10C9-044、10C9-045、10C9-046、10C9-047、10C9-048、10C9-049、
The VL sequences of 10C9-050,10C9-051,10C9-052,10C9-053,10C9-056 such as SEQ ID NO:Shown in 8-21, remaining
The VL sequences of clone such as SEQ ID NO:Shown in 2.
2.4 monoclonal antibody specificities are identified
In order to verify whether 10C9 specifically binds HPV18, we by immunofluorescence method detect 10C9 from it is different
The combination of patient's sample.Immunofluorescence results are as shown in fig. 7,10C9 can cervical tissue of the specific recognition from patient HPV18
Sample, and show very strong green Positive fluorescence signal, but in HPV16, the cervical tissue sample dyeing of HPV44 and Healthy People
In do not see green Positive fluorescence signal.
3.HPV18 infects ELISA detection kit
Will be one or more as capture antibody in said monoclonal antibody, preparation can specific recognition HPV capsid eggs
The detection antibody of white either HPV viruse (preferably HPV18 capsid proteins or HPV18 viruses), be equipped with it is known in the art other
Coherent detection reagent may make up HPV18 infection ELISA detection kits.
We use HPV18 L1 protein immunization new zealand white rabbits, prepare the Anti-TNF-α of anti-HPV18 L1 glutelins
Body.The specific method is as follows：It carried out just exempting from the 0th week, every takes the protein solution of 500 μ l 0.2mg/ml and 500 μ l Freunds complete
Adjuvant progress is fully emulsified, forms the emulsion of Water-In-Oil, carries out multiple spot dorsal sc injection and is immunized, it is big that 2 New Zealand are immunized
White rabbit.Respectively in the 2nd week, 5 weeks, 8 weeks, 11 weeks booster immunizations 4 times, the polypeptide of every immune 500 μ l x 0.2mg/ml is molten every time
The emulsion of liquid and 500 μ l incomplete Freund's adjuvants；6th week, 9 weeks, blood sampling detection in 12 weeks.
ELISA is the results show that two new zealand white rabbits 5 of the L1 protein immunizations can induce out up to after exempting from
1.9x107The High-titre antiserum of extension rate prompts us to have good immunogenicity by homemade L1 albumen, this is polyclonal
For serum by purifying, the detection antibody in being developed as subsequent detection reagent is named as PAb-18L1.
Grope by condition and optimize, we are used as detection antibody structure using 10C9 as capture antibody and PAb-18L1
The kit of ELISA is built.It is detected by patient's sample, it has been found that our other HPV of ELISA detection kit nonrecognition
The patient's sample of hypotype (as HPV16, HPV35, HPV39, HPV53, HPV 56, HPV58, HPV66), specific recognition
HPV18 patient's samples (Fig. 8).It can be seen that it is specific detection that quick diagnosis reagent kit, which is immunized, in the ELISA that we prepare
HPV18 patient's samples.In addition experimental result is shown, the ELISA detection kit prepared by us is for HPV18 L1 albumen
Sensitivity is 0.2ng (Fig. 9), and the sensitivity for the pseudovirus of HPV18 is 2.9ng (Figure 10).
The foregoing is merely presently preferred embodiments of the present invention, is not intended to limit the invention, it is all the present invention spirit and
Within principle, any modification, equivalent replacement, improvement and so on should all be included in the protection scope of the present invention.
Sequence table
<120>It is a kind of can specific recognition HPV18 L1 albumen monoclonal antibody and its application
<160> 21
<170> SIPOSequenceListing 1.0
<210> 1
<211> 117
<212> PRT
<213>Artificial sequence
<400> 1
Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu
1 5 10 15
Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe
50 55 60
Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr
65 70 75 80
Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys
85 90 95
Ala Arg Ser Gly Gly Tyr Phe Phe Asp Tyr Trp Gly Gln Gly Thr Thr
100 105 110
Leu Thr Val Ser Ser
115
<210> 2
<211> 113
<212> PRT
<213>Artificial sequence
<400> 2
Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly
1 5 10 15
Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
20 25 30
Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Thr
85 90 95
Thr His Val Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105 110
Arg
<210> 3
<211> 121
<212> PRT
<213>Artificial sequence
<400> 3
Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu
1 5 10 15
Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Ser Leu Lys Trp Met
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe
50 55 60
Lys Gly Arg Phe Gly Phe Ser Leu Glu Thr Ser Ala Thr Thr Ala Tyr
65 70 75 80
Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys
85 90 95
Ser Arg Gly Ser Tyr Gly Arg Ser Tyr Glu Gly Phe Ala Tyr Trp Gly
100 105 110
Gln Gly Thr Leu Val Thr Val Ser Ala
115 120
<210> 4
<211> 113
<212> PRT
<213>Artificial sequence
<400> 4
Asp Ile Val Met Thr Gln Ala Ala Pro Ser Val Pro Val Thr Pro Gly
1 5 10 15
Glu Ser Val Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser
20 25 30
Asn Gly Asn Thr Tyr Leu Tyr Trp Phe Leu Gln Arg Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Arg Met Ser Asn Leu Ala Ser Gly Val Ser
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Ala Phe Thr Leu Arg Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln His
85 90 95
Leu Glu Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
100 105 110
Arg
<210> 5
<211> 117
<212> PRT
<213>Artificial sequence
<400> 5
Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu
1 5 10 15
Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Ile Thr Asn Tyr
20 25 30
Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met
35 40 45
Gly Trp Ile Asn Thr Cys Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe
50 55 60
Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr
65 70 75 80
Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys
85 90 95
Ala Arg Ser Gly Gly Tyr Phe Phe Asp Tyr Trp Gly Gln Gly Thr Thr
100 105 110
Leu Thr Val Ser Ser
115
<210> 6
<211> 117
<212> PRT
<213>Artificial sequence
<400> 6
Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu
1 5 10 15
Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Tyr Phe Thr Asn Tyr
20 25 30
Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met
35 40 45
Gly Trp Ile Asn Thr Tyr Phe Gly Glu Pro Thr Tyr Ala Asp Asp Phe
50 55 60
Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr
65 70 75 80
Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys
85 90 95
Ala Arg Ser Gly Gly Tyr Phe Phe Asp Tyr Trp Gly Gln Gly Thr Thr
100 105 110
Leu Thr Val Ser Ser
115
<210> 7
<211> 117
<212> PRT
<213>Artificial sequence
<400> 7
Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu
1 5 10 15
Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe
50 55 60
Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr
65 70 75 80
Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys
85 90 95
Ser Arg Ser Gly Gly Tyr Phe Phe Asp Tyr Trp Gly Gln Gly Thr Thr
100 105 110
Leu Thr Val Ser Ser
115
<210> 8
<211> 113
<212> PRT
<213>Artificial sequence
<400> 8
Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly
1 5 10 15
Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Arg
20 25 30
Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Thr
85 90 95
Thr His Val Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105 110
Arg
<210> 9
<211> 113
<212> PRT
<213>Artificial sequence
<400> 9
Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly
1 5 10 15
Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
20 25 30
Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Gly Gln Thr
85 90 95
Thr His Val Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105 110
Arg
<210> 10
<211> 113
<212> PRT
<213>Artificial sequence
<400> 10
Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly
1 5 10 15
Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
20 25 30
Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Lys Leu Leu Ile Tyr Asp Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Thr
85 90 95
Thr His Val Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105 110
Arg
<210> 11
<211> 113
<212> PRT
<213>Artificial sequence
<400> 11
Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly
1 5 10 15
Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
20 25 30
Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Thr
85 90 95
Thr His Val Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105 110
Arg
<210> 12
<211> 113
<212> PRT
<213>Artificial sequence
<400> 12
Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly
1 5 10 15
Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
20 25 30
Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Thr
85 90 95
Thr His Val Ser Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105 110
Arg
<210> 13
<211> 113
<212> PRT
<213>Artificial sequence
<400> 13
Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly
1 5 10 15
Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Leu
20 25 30
Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Thr
85 90 95
Thr His Val Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105 110
Arg
<210> 14
<211> 113
<212> PRT
<213>Artificial sequence
<400> 14
Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly
1 5 10 15
Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Arg
20 25 30
Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Thr
85 90 95
Thr His Val Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105 110
Arg
<210> 15
<211> 113
<212> PRT
<213>Artificial sequence
<400> 15
Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly
1 5 10 15
Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
20 25 30
Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asn Leu Gly Val Tyr Phe Cys Asn Gln Thr
85 90 95
Thr His Val Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105 110
Arg
<210> 16
<211> 113
<212> PRT
<213>Artificial sequence
<400> 16
Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly
1 5 10 15
Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
20 25 30
Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Lys Leu Leu Ile Tyr Lys Val Ile Asn Arg Phe Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asn Leu Gly Val Tyr Phe Cys Ser Gln Thr
85 90 95
Thr His Val Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105 110
Arg
<210> 17
<211> 110
<212> PRT
<213>Artificial sequence
<400> 17
Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly
1 5 10 15
Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
20 25 30
Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Lys Leu Leu Ile Tyr Lys Val Cys Asn Arg Phe Ser Gly Pro Gly
50 55 60
Phe Tyr Leu Leu Pro Phe Phe Ser Val Ser Gly Ser Leu Arg His Leu
65 70 75 80
Pro Ala Leu Val Pro Ala Glu Thr Gly Ser Val Ser Glu Thr Ala Asp
85 90 95
Leu Leu Cys Phe Pro Phe Leu Trp Cys Ser Gly Pro Phe Xaa
100 105 110
<210> 18
<211> 113
<212> PRT
<213>Artificial sequence
<400> 18
Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly
1 5 10 15
Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Val
20 25 30
Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asn Leu Gly Val Tyr Phe Cys Ser Gln Thr
85 90 95
Thr His Val Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105 110
Arg
<210> 19
<211> 114
<212> PRT
<213>Artificial sequence
<400> 19
Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly
1 5 10 15
Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
20 25 30
Asn Gly Asn Phe Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Lys Leu Leu Ile Tyr Lys Val Cys Asn Arg Phe Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asn Leu Gly Val Tyr Phe Cys Ser Gln Thr
85 90 95
Thr Leu Val Pro Pro Thr Phe Arg Trp Trp Tyr Gln Thr Gly Asn Gln
100 105 110
Thr Xaa
<210> 20
<211> 113
<212> PRT
<213>Artificial sequence
<400> 20
Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly
1 5 10 15
Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
20 25 30
Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asn Leu Gly Val Tyr Phe Cys Ser Gln Thr
85 90 95
Thr His Phe Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105 110
Arg
<210> 21
<211> 114
<212> PRT
<213>Artificial sequence
<400> 21
Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly
1 5 10 15
Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
20 25 30
Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Thr
85 90 95
Thr His Val Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105 110
Arg Xaa
Claims (10)
1. it is a kind of can specific recognition HPV18L1 albumen monoclonal antibody, which is characterized in that including heavy chain region and light chain area,
The sequence of the wherein described heavy chain region is SEQ ID NO:1 or 3, or with SEQ ID NO:1 or 3 sequences with 80% consistency
Row；The sequence in the light chain area is SEQ ID NO:2 or 4, or with SEQ ID NO:1 or 3 sequences with 80% consistency.
2. monoclonal antibody according to claim 1, which is characterized in that SEQ ID NO:There are three CDR regions for tool in 1, divide
It Wei not 26-33 sections, 52-58 sections and 97-106 sections.
3. monoclonal antibody according to claim 1, which is characterized in that SEQ ID NO:There are three CDR regions for tool in 2, divide
It Wei not 27-37 sections, 55-57 sections and 95-103 sections.
4. monoclonal antibody according to claim 1, which is characterized in that the sequence of the heavy chain region is selected from SEQ ID NO:
1、3、5-7。
5. monoclonal antibody according to claim 1, which is characterized in that the sequence in the light chain area is selected from SEQ ID NO:
2、4、8-21。
6. monoclonal antibody according to claim 1, which is characterized in that the heavy chain domain sequence of the monoclonal antibody is
SEQ ID NO:1, sequence of light chain is SEQ ID NO:19.
7. monoclonal antibody according to claim 1, which is characterized in that the heavy chain domain sequence of the monoclonal antibody is
SEQ ID NO:6, sequence of light chain is SEQ ID NO:2.
8. application of the monoclonal antibody in preparing HPV18 detection reagents described in any one of claim 1-7.
9. a kind of kit for detecting HPV18, which is characterized in that including the Dan Ke described in any one of claim 1-7
Grand antibody.
10. kit according to claim 9, which is characterized in that the kit is ELISA kit, including capture
Antibody and detection antibody, the capture antibody are the monoclonal antibody described in any one of claim 1-7, the detection antibody
For the polyclonal antibody for using HPV18L1 glutelins to be prepared as antigen.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810110881.0A CN108276491B (en) | 2018-02-05 | 2018-02-05 | Monoclonal antibody capable of specifically recognizing HPV18L1 protein and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810110881.0A CN108276491B (en) | 2018-02-05 | 2018-02-05 | Monoclonal antibody capable of specifically recognizing HPV18L1 protein and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108276491A true CN108276491A (en) | 2018-07-13 |
| CN108276491B CN108276491B (en) | 2021-01-12 |
Family
ID=62807523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810110881.0A Active CN108276491B (en) | 2018-02-05 | 2018-02-05 | Monoclonal antibody capable of specifically recognizing HPV18L1 protein and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108276491B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110964104A (en) * | 2019-12-25 | 2020-04-07 | 源道隆（苏州）医学科技有限公司 | Protein capable of binding HPV18 virus and application thereof |
| CN111793136A (en) * | 2020-05-11 | 2020-10-20 | 廊坊天光生物技术有限公司 | NMP22 antibody pair and application thereof |
| CN114230659A (en) * | 2021-11-12 | 2022-03-25 | 郑州大学 | anti-HPV 53L1 protein monoclonal antibody, and preparation and application thereof |
| CN115112885A (en) * | 2022-06-18 | 2022-09-27 | 广州臻卓生物技术有限公司 | HPV detection kit and preparation method and application thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996029413A2 (en) * | 1995-03-22 | 1996-09-26 | Merck & Co., Inc. | Dna encoding human papilloma virus type 18 |
| US20020197264A1 (en) * | 1995-10-02 | 2002-12-26 | Georgetown University School Of Medicine | Protecting against canine oral papillomavirus (COPV) |
| US20090104215A1 (en) * | 2005-09-13 | 2009-04-23 | Irena Ekiel | Methods and compositions for modulating tumor cell activity |
| CN105175537A (en) * | 2012-06-08 | 2015-12-23 | 厦门大学 | Broad-spectrum monoclonal antibody resisting HPV L1 protein or antigen binding fragment thereof and application of broad-spectrum monoclonal antibody and antigen binding fragment |
| CN105524166A (en) * | 2014-09-28 | 2016-04-27 | 艾托金生物医药（苏州）有限公司 | Monoclonal antibody for identifying HPV18 positive cervical epithelial cancer cells, and applications thereof |
| CN105669859A (en) * | 2014-11-12 | 2016-06-15 | 北京康乐卫士生物技术股份有限公司 | Human papilloma virus 18 monoclonal antibody and application thereof |
| CN105753980A (en) * | 2016-03-29 | 2016-07-13 | 上海市普陀区中心医院 | HPV18 E6 monoclonal antibody and preparation method and application thereof |
| US20160368974A1 (en) * | 2013-12-12 | 2016-12-22 | Umc Utrecht Holding B.V. | Immunoglobulin-like molecules directed against fibronectin-eda |
-
2018
- 2018-02-05 CN CN201810110881.0A patent/CN108276491B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996029413A2 (en) * | 1995-03-22 | 1996-09-26 | Merck & Co., Inc. | Dna encoding human papilloma virus type 18 |
| US20020197264A1 (en) * | 1995-10-02 | 2002-12-26 | Georgetown University School Of Medicine | Protecting against canine oral papillomavirus (COPV) |
| US20090104215A1 (en) * | 2005-09-13 | 2009-04-23 | Irena Ekiel | Methods and compositions for modulating tumor cell activity |
| CN105175537A (en) * | 2012-06-08 | 2015-12-23 | 厦门大学 | Broad-spectrum monoclonal antibody resisting HPV L1 protein or antigen binding fragment thereof and application of broad-spectrum monoclonal antibody and antigen binding fragment |
| US20160368974A1 (en) * | 2013-12-12 | 2016-12-22 | Umc Utrecht Holding B.V. | Immunoglobulin-like molecules directed against fibronectin-eda |
| CN105524166A (en) * | 2014-09-28 | 2016-04-27 | 艾托金生物医药（苏州）有限公司 | Monoclonal antibody for identifying HPV18 positive cervical epithelial cancer cells, and applications thereof |
| CN105669859A (en) * | 2014-11-12 | 2016-06-15 | 北京康乐卫士生物技术股份有限公司 | Human papilloma virus 18 monoclonal antibody and application thereof |
| CN105753980A (en) * | 2016-03-29 | 2016-07-13 | 上海市普陀区中心医院 | HPV18 E6 monoclonal antibody and preparation method and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| SUMANTA DEY等: "Rational Design of Peptide Vaccines Against Multiple Types of Human Papillomavirus", 《CANCER INFORMATICS》 * |
| SUNANDA BAIDYA等: "Epitope design of L1 protein for vaccine production against Human Papilloma Virus types 16 and 18", 《BIOINFORMATION》 * |
| 贾士东等: "HPV18L1基因重组DNA构建及其免疫小鼠体内特异抗体的测定", 《中国免疫学杂志》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110964104A (en) * | 2019-12-25 | 2020-04-07 | 源道隆（苏州）医学科技有限公司 | Protein capable of binding HPV18 virus and application thereof |
| CN110964104B (en) * | 2019-12-25 | 2021-08-13 | 南京薇熙生物医药科技有限公司 | Protein capable of binding HPV18 virus and application thereof |
| CN111793136A (en) * | 2020-05-11 | 2020-10-20 | 廊坊天光生物技术有限公司 | NMP22 antibody pair and application thereof |
| CN114230659A (en) * | 2021-11-12 | 2022-03-25 | 郑州大学 | anti-HPV 53L1 protein monoclonal antibody, and preparation and application thereof |
| CN114230659B (en) * | 2021-11-12 | 2023-05-23 | 郑州大学 | anti-HPV 53L1 protein monoclonal antibody, preparation and application thereof |
| CN115112885A (en) * | 2022-06-18 | 2022-09-27 | 广州臻卓生物技术有限公司 | HPV detection kit and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108276491B (en) | 2021-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU593193B2 (en) | Diagnostic peptides of human papilloma virus | |
| CN108276491A (en) | monoclonal antibody capable of specifically recognizing HPV 18L 1 protein and application thereof | |
| AU624485B2 (en) | Immunogenic regions on the e7 protein of human papillomavirus type 16 | |
| AU697743B2 (en) | Papillomavirus vaccines | |
| Rubio et al. | The N-terminal region of the human papillomavirus L2 protein contains overlapping binding sites for neutralizing, cross-neutralizing and non-neutralizing antibodies | |
| US6346377B1 (en) | Screening for papilloma viruses | |
| CN105669859B (en) | Human papilloma virus 18 type monoclonal antibody and application thereof | |
| CN107043408B (en) | Antigen-norovirus P-domain monomers and dimers, antigen-norovirus P-particle molecules, and methods of making and using the same | |
| US5968522A (en) | Immunogenic compositions and antibodies directed against human papillomavirus type 49 (HPV 49), type 50 (HPV 50), type 54 (HPV 54), and type 55 (HPV 55). | |
| CN101426810A (en) | Hpv-18-based papillomavirus vaccine | |
| CN108586607A (en) | The preparation method and applications of anti-HPV16 L1 protein monoclonal antibodies | |
| JP2010148514A (en) | Production of human papillomavirus capsid protein and virus-like particle | |
| MX2011013744A (en) | Novel human papillomavirus (hpv) protein constructs and their use in the prevention of hpv disease. | |
| CN101538319A (en) | Polypeptide for detecting polytype human papilloma virus and application thereof | |
| CN105713087A (en) | Human papillomavirus 58 monoclonal antibody and application thereof | |
| CN106957361A (en) | The specific antibody of HPV E6 albumen and its application | |
| CN101426811A (en) | Hpv-16-based papillomavirus vaccine | |
| US6485728B2 (en) | Formalin-Inactivated human papillomavirus L1 protein vaccine | |
| CN113717283B (en) | Monoclonal antibody for resisting hepatitis B virus e antigen and application thereof | |
| Iwasaki et al. | Detection of capsid antigen of human papillomavirus (HPV) in benign lesions of female genital tract using anti‐HPV monoclonal antibody | |
| CN101280316B (en) | Therapeutic vaccine for human cervical carcinoma | |
| US6284532B1 (en) | Purified human papillomavirus | |
| Embers et al. | Differential antibody responses to a distinct region of human papillomavirus minor capsid proteins | |
| JPH09500285A (en) | Papilloma virus, its detection reagent, and therapeutic agent for diseases caused thereby | |
| CN102443060A (en) | Anti-HPV (human papilloma virus) antibody and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20200611 Address after: Room 359, block a, phase I, Zhongdan Ecological Life Science Industrial Park, No. 3-1, xinjinhu Road, Jiangbei new district, Nanjing City, Jiangsu Province Applicant after: Nanjing Weixi Biomedical Technology Co., Ltd Address before: Suzhou City, Jiangsu Province, Suzhou Industrial Park 215123 Xinghu Street No. 218 BioBAY building B2 room 513 Applicant before: Yuandaolong (Suzhou) Medical Technology Co.,Ltd. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220507 Address after: Room 513, building B2, bio nano Park, 218 Xinghu street, Suzhou Industrial Park, Suzhou area, China (Jiangsu) pilot Free Trade Zone, Suzhou, Jiangsu 215000 Patentee after: Y-CLONE MEDICAL SCIENCE Co.,Ltd. Address before: Room 359, block a, phase I, Zhongdan Ecological Life Science Industrial Park, no.3-1, xinjinhu Road, Jiangbei new district, Nanjing City, Jiangsu Province, 210043 Patentee before: Nanjing Weixi Biomedical Technology Co.,Ltd. |